... level of EGFR in cancer tissues is correlated with prognosis, but not with responsiveness to EGFR tyrosine kinase inhibitor treatment, suggesting that, independent of its kinase activity, EGFR may ...
... BCR-ABL point mutations and support the use of other tyrosine kinase inhibitors to treat a broad spectrum ... geting both BCR-ABL and LYN kinases may prove beneficial in certain circumstances of imatinib ...
... of stem cell disorders. CML is typically treated with the targeted therapy imatinib (Gleevec), a tyrosine kinase inhibitor.
“Gleevec does dramatically improve prognosis of CML patients,” notes ...
... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, said Massimo Cristofanilli, M. ... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, to become commercially available ...
... than anything previously seen in animals, which may help scientists understand the fundamentals of how all tyrosine kinase signaling works. Despite their extreme diversity, Monosiga kinases time and ...
... . Although pre-clinical studies indicated therapeutics inhibiting a group of proteins known as receptor tyrosine kinases (RTKs) would likely be beneficial to individuals with ...
... and Molecular Biology at Monash University said their work showed that the enzymes known as protein tyrosine kinases (PTKs) had a greater role than previously thought in the rate of growth and tumour ...
... to test."
ErbB2 and Brk go hand-in-hand
ErbB2 is a member of a family of enzymes called receptor tyrosine kinases -- cell-surface molecules that goad cells into proliferating when ...
... tumor suppressor pathway, which is involved in response to DNA damage and cell death; and the receptor tyrosine kinase pathway that carries signals that control cell growth.
Chin said that the most ...
... of lung cancer.
The two mutations they screened for were a deletion in exon 19 of the receptor's tyrosine kinase domain, and a mutation in exon 21. Tumors with EGFR mutations are more frequently ...
... University of Hong Kong.
"Currently, gefitinib and other EGFR tyrosine kinase inhibitors are considered as second line therapy for advanced non-small-cell lung cancers, meaning ...
... a potential therapeutic strategy for pancreatic cancer has been developed. Erlotinib is a small molecule tyrosine kinase inhibitor that efficiently blocks EGFR. Preliminary results of phase III trial ...
... the long-standing mystery of what Agrin binds to at the developing junction to activate the receptor tyrosine kinase MuSK," says molecular biologist Martin Raff of the MRC laboratory for Molecular ...
... operates as a giant molecular machine, with each part in close communication with the others.
"It is clear that tyrosine kinase inhibitors do not simply inhibit the enzyme, but rather remodel the ...
... kinases (ERBB4, KDR and FGFR4). These genes code for cell receptors coupled to members of the tyrosine kinase family of enzymes, which are considered prime targets for new cancer therapies.
After ...
